SCHEMBL2767154

SCHEMBL2767154

COCOc1ccc(N2CCNCC2)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 7/20 0.56
CHRNB2 P17787 2/20 0.47
CHRNA4 P43681 2/20 0.47
HTR3E A5X5Y0 4/20 0.46
HTR3B O95264 4/20 0.46
HTR3A P46098 4/20 0.46
HTR3D Q70Z44 4/20 0.46
HTR3C Q8WXA8 4/20 0.46
ALK Q9UM73 1/20 0.46
SIGMAR1 Q99720 3/20 0.45
HTR1A P08908 3/20 0.45
HTR1D P28221 1/20 0.45
HTR1B P28222 1/20 0.45
HTR7 P34969 2/20 0.44
HTR2C P28335 2/20 0.44
TP53 P04637 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8182707 0.84 ADRB1 (0.65) ADRB1CHRNB2CHRNA4HTR3EHTR3B
SCHEMBL16742541 0.83 INSR (0.46) ALKHTR2CTP53THRBHTR2B
SCHEMBL2767207 0.78 SLC6A4 (0.59) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL27638449 0.76 MAPT (0.42) HTR1AHTR7CYP3A4HTTHTR6
SCHEMBL17455228 0.76 ADRB1 (0.67) ADRB1CHRNB2CHRNA4HTR3EHTR3B
SCHEMBL2767494 0.75 SIGMAR1 (0.56) SIGMAR1HTR1AHTR6MAPT
SCHEMBL27638464 0.75 MAPT (0.41) SIGMAR1HTTHTR6ALDH1A1MAPT
SCHEMBL1639487 0.75 ADRB1 (0.65) ADRB1CHRNB2CHRNA4HTR3EHTR3B
SCHEMBL14922739 0.74 CHRNB2 (0.54) ADRB1CHRNB2CHRNA4HTR3EHTR3B
SCHEMBL29042563 0.74 ADRB1 (0.59) ADRB1CHRNB2CHRNA4HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627871-B1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE ASKA PHARM CO LTD (JP) 2010-04-14 EP disclosed
CN-100467449-C Cyclic aminophenyl sulfamate derivative ASKA PHARM CO LTD (JP) 2009-03-11 CN disclosed
US-7449466-B2 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-11-11 US disclosed
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
CN-1823039-A Cyclic aminophenyl sulfamate derivative ASKA PHARM CO LTD (JP) 2006-08-23 CN disclosed
EP-1627871-A1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE Teikoku Hormone Mfg. Co., Ltd. (JP) 2006-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative SHBG, STS, ARSA ADRB1 852/4885CHRNB2 1813/4885CHRNA4 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.